Clinical trial · Interventional
Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions
Application of a New System of Ultrasound (US) Guided - Radiofrequency Ablation (RFA) on Explanted Pancreas From Patients With Solid Pancreatic Masses: Study of Efficacy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): resectable pancreatic adenocarcinoma and neuroendocrine pancreatic neoplasms are difficult to be enrolled. Pancreatic resectable cancers are treated nowadays with chemotherapy and big neuroedocrine pancreatic lesions rare
Summary
Brief summary (as posted)
The study investigates the feasibility and the efficacy to treat pancreatic solid lesions as pancreatic adenocarcinomas (PDAC) and neuroendocrine tumors (NET) with ex-vivo radiofrequency ablation (RFA) under ultrasound (US) control. The study intent is to define the optimal radiofrequency ablation POWER of the system in terms of maximum sizes (diameters) of histological coagulative necrosis obtained at pathological samples. Results will be useful to define the optimal settings to ablate pancreatic solid lesions (PDAC and neuroendocrine tumours).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endoscopic Ultrasound | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Radiofrequency Ablation | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions | Procedure | — | UNRESOLVED |
| ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions | Procedure | — | UNRESOLVED |
| ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- resected PDAC without neoadjuvant chemotherapy treatment
- description
- Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
- interventionNames
- Procedure: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions
- Procedure: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions
- Procedure: ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions
- type
- EXPERIMENTAL
- label
- resected PDAC with neoadjuvant chemotherapy treatment
- description
- Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
- interventionNames
- Procedure: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions
- Procedure: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: pancreatic solid lesion presence (pancreatic adenocarcinoma and neuroendocrine tumors) resected during pancreatic surgery - Exclusion Criteria: no signature on informed consent \-
References
Publications (0)
Data not yet available